Drugs https://www.bioworld.com/rss en-us Drugs to Watch 2025: 11 potential blockbusters in the making Drugs to Watch features 11 candidates or approved therapeutics that may well revolutionize treatments or become blockbusters. The 12th annual report has a strong track record. Twelve of the 13 drugs from the 2024 Drugs to Watch report have been approved and launched.]]> http://www.bioworld.com/articles/716345 Tue, 14 Jan 2025 10:00:00 -0500 https://www.bioworld.com/articles/716345-drugs-to-watch-2025-11-potential-blockbusters-in-the-making Drugs to Watch 2025 report cover Drugs to Watch 2025: 11 potential blockbusters in the making Drugs to Watch features 11 candidates or approved therapeutics that may well revolutionize treatments or become blockbusters. The 12th annual report has a strong track record. Twelve of the 13 drugs from the 2024 Drugs to Watch report have been approved and launched.]]> http://www.bioworld.com/articles/716200 Wed, 08 Jan 2025 10:00:00 -0500 https://www.bioworld.com/articles/716200-drugs-to-watch-2025-11-potential-blockbusters-in-the-making Drugs to Watch 2025 report cover Pfizer’s Beqvez taking on Hemgenix with FDA nod in hemophilia B http://www.bioworld.com/articles/708014 Fri, 26 Apr 2024 00:00:00 -0400 https://www.bioworld.com/articles/708014-pfizers-beqvez-taking-on-hemgenix-with-fda-nod-in-hemophilia-b Red blood cells on blue background Australian incubator developing drugs, devices for dementia http://www.bioworld.com/articles/706129 Tue, 27 Feb 2024 12:00:00 -0500 https://www.bioworld.com/articles/706129-australian-incubator-developing-drugs-devices-for-dementia Elderly woman holding illustration of brain with missing puzzle piece Australian incubator developing drugs, devices for dementia http://www.bioworld.com/articles/706096 Mon, 26 Feb 2024 12:00:00 -0500 https://www.bioworld.com/articles/706096-australian-incubator-developing-drugs-devices-for-dementia Elderly woman holding illustration of brain with missing puzzle piece Deadline nears with no consensus on broader WTO COVID-19 waiver http://www.bioworld.com/articles/705934 Tue, 20 Feb 2024 12:00:00 -0500 https://www.bioworld.com/articles/705934-deadline-nears-with-no-consensus-on-broader-wto-covid-19-waiver WTO logo Drugs to Watch 2024: A baker’s dozen of potential blockbusters and gamechangers Drugs to Watch features 13 drugs that highlight an inflection point where amazing, merging tech is finally paying off with ADCs and CRISPR/Cas9 and bispecifics, Matthew Arnold, principal analyst, Clarivate Life Sciences and Healthcare, told BioWorld.]]> http://www.bioworld.com/articles/704448 Tue, 09 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704448-drugs-to-watch-2024-a-bakers-dozen-of-potential-blockbusters-and-gamechangers Drugs to Watch 2024: A baker’s dozen of potential blockbusters and gamechangers Drugs to Watch features 13 drugs that highlight an inflection point where amazing, merging tech is finally paying off with ADCs and CRISPR/Cas9 and bispecifics, Matthew Arnold, principal analyst, Clarivate Life Sciences and Healthcare, told BioWorld.]]> http://www.bioworld.com/articles/704412 Mon, 08 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704412-drugs-to-watch-2024-a-bakers-dozen-of-potential-blockbusters-and-gamechangers US lawmakers: Expansion of COVID-19 IP waiver unnecessary http://www.bioworld.com/articles/704164 Tue, 02 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704164-us-lawmakers-expansion-of-covid-19-ip-waiver-unnecessary U.S. intellectual property illustration Industry learning its ADCs better and better as deals abound http://www.bioworld.com/articles/704158 Fri, 29 Dec 2023 12:00:00 -0500 https://www.bioworld.com/articles/704158-industry-learning-its-adcs-better-and-better-as-deals-abound Top Trends Therapeutics, pill, syringe Leqembi a taste of things to come in Alzheimer's http://www.bioworld.com/articles/704186 Thu, 28 Dec 2023 12:00:00 -0500 https://www.bioworld.com/articles/704186-leqembi-a-taste-of-things-to-come-in-alzheimers Top Trends Drug Pricing, capsule with coins Industry, FDA mindset coming around to psychedelics http://www.bioworld.com/articles/704116 Wed, 27 Dec 2023 12:00:00 -0500 https://www.bioworld.com/articles/704116-industry-fda-mindset-coming-around-to-psychedelics Top Trends Therapeutics, pill, syringe Samsung, Celltrion set record targets as S. Korea banks on Bio Economy 2.0 http://www.bioworld.com/articles/701476 Tue, 03 Oct 2023 12:00:00 -0400 https://www.bioworld.com/articles/701476-samsung-celltrion-set-record-targets-as-s-korea-banks-on-bio-economy-20 Samsung Biologics Bio Campus II Birds-eye view of Samsung Biologics Bio Campus II. Credit: Samsung Biologics Samsung, Celltrion set record targets as S. Korea banks on Bio Economy 2.0 http://www.bioworld.com/articles/701365 Thu, 28 Sep 2023 09:00:00 -0400 https://www.bioworld.com/articles/701365-samsung-celltrion-set-record-targets-as-s-korea-banks-on-bio-economy-20 Samsung Biologics Bio Campus II Birds-eye view of Samsung Biologics Bio Campus II. Credit: Samsung Biologics Vesalius closes €95M fund IV, with 60% going to drug development http://www.bioworld.com/articles/698507 Thu, 29 Jun 2023 12:00:00 -0400 https://www.bioworld.com/articles/698507-vesalius-closes-95m-fund-iv-with-60-going-to-drug-development 3D Euro symbol Sarepta sets a $3.2M price tag for Elevidys http://www.bioworld.com/articles/698267 Fri, 23 Jun 2023 12:00:00 -0400 https://www.bioworld.com/articles/698267-sarepta-sets-a-32m-price-tag-for-elevidys Drug pricing illustration Gamida’s gamble on Omisirge pays off as FDA approves blood cancer cell therapy http://www.bioworld.com/articles/696174 Tue, 18 Apr 2023 00:00:00 -0400 https://www.bioworld.com/articles/696174-gamidas-gamble-on-omisirge-pays-off-as-fda-approves-blood-cancer-cell-therapy At the head of the biosimilar pack, Amgen’s challenger to Humira launches in the US http://www.bioworld.com/articles/693829 Tue, 31 Jan 2023 12:00:00 -0500 https://www.bioworld.com/articles/693829-at-the-head-of-the-biosimilar-pack-amgens-challenger-to-humira-launches-in-the-us Amgevita and Humira injector pens <em>Drugs to Watch:</em> This time it’s personalized Drugs to Watch 2023 report primarily features treatments targeted to a particular biomarker, signaling the advance and increasing potential of personalized medicines. The 15 drugs on the list are anticipated to either register sales of more than $1 billion by 2027 or be clinical game changers. Nine are predicted to hit $1 billion annual sales each in China by 2030.]]> http://www.bioworld.com/articles/693239 Wed, 11 Jan 2023 12:00:00 -0500 https://www.bioworld.com/articles/693239-emdrugs-to-watch-em-this-time-its-personalized Drugs to Watch 2023 Inflation Reduction Act first major US victory on Rx prices, but likely not the last http://www.bioworld.com/articles/692804 Tue, 27 Dec 2022 12:00:00 -0500 https://www.bioworld.com/articles/692804-inflation-reduction-act-first-major-us-victory-on-rx-prices-but-likely-not-the-last WLB-83038, a small-molecule candidate with new dual mode of action to treat pain http://www.bioworld.com/articles/689682 Thu, 15 Sep 2022 09:00:00 -0400 https://www.bioworld.com/articles/689682-wlb-83038-a-small-molecule-candidate-with-new-dual-mode-of-action-to-treat-pain Pill over molecule structures Discovery of novel ponatinib analogues with reduced cardiotoxicity http://www.bioworld.com/articles/689633 Wed, 14 Sep 2022 09:00:00 -0400 https://www.bioworld.com/articles/689633-discovery-of-novel-ponatinib-analogues-with-reduced-cardiotoxicity Teva’s cost of ending US opioid suits could add up to $4.35B http://www.bioworld.com/articles/521085 Wed, 27 Jul 2022 12:00:00 -0400 https://www.bioworld.com/articles/521085-tevas-cost-of-ending-us-opioid-suits-could-add-up-to-435b Oxycodone pills and bottle Medicare outpatient draft rich with pass-through opportunities, but 340B drug tweak delayed http://www.bioworld.com/articles/520844 Tue, 19 Jul 2022 13:00:00 -0400 https://www.bioworld.com/articles/520844-medicare-outpatient-draft-rich-with-pass-through-opportunities-but-340b-drug-tweak-delayed US Rx price negotiations edge toward reality http://www.bioworld.com/articles/520567 Thu, 07 Jul 2022 12:00:00 -0400 https://www.bioworld.com/articles/520567-us-rx-price-negotiations-edge-toward-reality USPTO, FDA join forces to prune drug patent thickets http://www.bioworld.com/articles/520462 Wed, 06 Jul 2022 12:00:00 -0400 https://www.bioworld.com/articles/520462-uspto-fda-join-forces-to-prune-drug-patent-thickets China to ramp up volume-based procurement policies for drugs and devices to control prices http://www.bioworld.com/articles/519965 Tue, 21 Jun 2022 12:00:00 -0400 https://www.bioworld.com/articles/519965-china-to-ramp-up-volume-based-procurement-policies-for-drugs-and-devices-to-control-prices Shipping container with flag of China China to ramp up volume-based procurement policies for drugs and devices to control prices http://www.bioworld.com/articles/519879 Fri, 17 Jun 2022 12:00:00 -0400 https://www.bioworld.com/articles/519879-china-to-ramp-up-volume-based-procurement-policies-for-drugs-and-devices-to-control-prices COVID-19 IP waiver on the line at WTO conference http://www.bioworld.com/articles/519736 Tue, 14 Jun 2022 12:00:00 -0400 https://www.bioworld.com/articles/519736-covid-19-ip-waiver-on-the-line-at-wto-conference Syringe and COVID-19 vaccine vials as question mark COVID-19 IP waiver on the line at WTO conference http://www.bioworld.com/articles/519704 Mon, 13 Jun 2022 12:00:00 -0400 https://www.bioworld.com/articles/519704-covid-19-ip-waiver-on-the-line-at-wto-conference